Is best-corrected visual acuity an appropriate outcome measure for treatment trials in Stargardt disease? A multicenter longitudinal cohort study (the ProgStar Study with H Scholl as principal investigator), seeked answers to this question.
Visual Acuity Change Over 24 Months and its Association With Foveal Phenotype and Genotype in Individuals With Stargardt Disease
ProgStar Study Report No. 10
Xiangrong Kong, Kaoru Fujinami, Rupert W. Strauss, Beatriz Munoz, Sheila K. West, Artur V. Cideciyan, Michel Michaelides, Mohamed Ahmed, Ann-Margret Ervin, Etienne Schönbach, Janet K. Cheetham, Hendrik P. N. Scholl, MD; for the ProgStar Study Group
Read the paper in JAMA Ophthalmology
Published online June 14, 2018. doi:10.1001/jamaophthalmol.2018.2198